Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129974 · ClinicalTrials.gov registry record · Phase 2
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00129974 is a Phase 2 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT00129974, a Phase 2 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer. The second purpose is to see if the side effects appear better than what is expected with standard chemotherapy.
Interventions
- DRUG pemetrexed and gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00129974
The ClinicalTrials.gov registry entry for NCT00129974 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pemetrexed and gemcitabine is the first listed.
NCT00129974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00129974 about?
NCT00129974 is a clinical study titled "Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer". The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer. The second purpose is to see if the side effects appear better than what is expected with standard chemothe...
What is the current status of trial NCT00129974?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2005-08. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00129974?
The interventions under investigation include: pemetrexed and gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00129974?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.